Back to Agendas
[V1-S3] For Enhancement of Industry-Government-Academia Collaboration in Japan (Part 1)
Session Chair(s)
Hideki Hanaoka, MD, PhD
, Chiba University Hospital, Japan
Toshio Miyata, MD
Executive Director, Health and Global Policy Institute, Japan
In April 2015, AMED, Japan Agency for Medical Research and Development, was established to enhance efficient research and development, from the basic scientific research to practical application, with consistency in the field of health care science in Japan. Creating innovative drugs from Japan is one of the most important elements of Japan’s growth strategy and a great chance for pharmaceutical industry at the same time. In this session, experts from academic departments, industry, and government will facilitate discussions on the challenges we have in collaboration among them, sharing the excellent practices from several ongoing activities.
Speaker(s)
Yasunori Yoshida
Food Safety Commission of Japan, Cabinet Office, Government of Japan, Japan
AMED’s Support for Translational Researches, Clinical Researches, and Clinical Trials
John H. Alexander, MD
Director, Cardiovascular Research; Vice Chief, Clinical Research, Cardiology, Duke Clinical Research Institute, United States
Activity of Duke Clinical Research Institute
Michihiko Wada, MD, PhD
Professor, Clinical and Translational Research Center, Keio University, Japan
A case of succeeded program designed to novel industry-government-academia collaboration
Have an account?